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Background: Radioembolization with Yttrium-90 (90Y) microspheres is becoming a
more widely used transcatheter treatment for unresectable hepatocellular carcinoma
(HCC). Using post-treatment 90Y positron emission tomography/computerized tomogra-
phy (PET/CT) scans, the distribution of microspheres within the liver can be determined
and quantitatively assessed. We studied the radiation dose of 90Y delivered to liver and
treated tumors.
Methods: This retrospective study of 56 patients with HCC, including analysis of 98 liver
tumors, measured and correlated the dose of radiation delivered to liver tumors and normal
liver tissue using glass microspheres (TheraSpheres®) to the frequency of complications
with modified response evaluation criteria in solid tumors (mRECIST). 90Y PET/CT and
triphasic liver CT scans were used to contour treated tumor and normal liver regions and
determine their respective activity concentrations. An absorbed dose factor was used to
convert the measured activity concentration (Bq/mL) to an absorbed dose (Gy).
Results:The 98 studied tumors received a mean dose of 169 Gy (mode 90–120 Gy; range
0–570 Gy). Tumor response by mRECIST criteria was performed for 48 tumors that had
follow-up scans. There were 21 responders (mean dose 215 Gy) and 27 non-responders
(mean dose 167 Gy). The association between mean tumor absorbed dose and response
suggests a trend but did not reach statistical significance (p=0.099). Normal liver tissue
received a mean dose of 67 Gy (mode 60–70 Gy; range 10–120 Gy).There was a statistically
significant association between absorbed dose to normal liver and the presence of two or
more severe complications (p=0.036).
Conclusion: Our cohort of patients showed a possible dose–response trend for the tumors.
Collateral dose to normal liver is non-trivial and can have clinical implications. These meth-
ods help us understand whether patient adverse events, treatment success, or treatment
failure can be attributed to the dose that the tumor or normal liver received.
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INTRODUCTION
HEPATOCELLULAR CARCINOMA
Hepatocellular carcinoma (HCC) affects approximately 500,000
people worldwide, representing the third leading cause of cancer
related deaths and the sixth most prevalent cancer (1, 2). Axel-
rod and von Leeuwen have reported that the incidence of HCC
has “more than doubled, from 2.6 to 5.2 per 100,000 population”
over the past 20 years, with an increase in mortality from 2.8 to
4.7 per 100,000 (1). Owing to this increase in incidence is the ear-
lier acquisition of hepatitis B and C in conjunction with high-risk
behavior (1). Additionally, the obesity epidemic has contributed
to an increase in non-alcoholic steatohepatitis (NASH), which can
eventually progress to fibrosis, cirrhosis, and HCC (1).
CURRENT TREATMENTS
The treatment of HCC has been problematic, since most patients
present at an advanced stage (3). In early stages of the disease,
surgical treatments – primarily resection and transplantation –
provide the best curative outcomes. Ideal candidates for resection
are those patients with small solitary tumors and preserved liver
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function, whereas patients who meet the Milan criteria and who
are not good candidates for resection often benefit from liver
transplantation (2). A disadvantage of resection, however, is that
patients’ remnant livers may not be able to support the neces-
sary hepatic functional demands, and there is a high potential for
recurrent disease (4).
Other treatment modalities include transarterial chemoem-
bolization (TACE), sorafenib, external beam radiation, and
radiofrequency ablation. In comparison to sorafenib and exter-
nal beam radiation, more local therapies such as radiofrequency
ablation, radioembolization, and TACE are able to deliver the
desired dose to the target with minimal toxicity to the system
(5). Supporting this statement, Dezarn et al. noted that the max-
imum external beam acceptable dose to the whole liver of 35 Gy
delivered in 1.8 Gy/day fractions is far below the 70 Gy typically
needed to destroy solid tumor lesions (6). The sensitivity of nor-
mal hepatic tissue to external beam radiation has given way to
more locally effective techniques. Stereotactic body radiotherapy
(SBRT), therefore, is usually reserved for those patients who have
well-defined tumors on MRI or CT, and the ability to treat safely
is limited by lesion number, distribution, and location (6).
An emerging and innovative practice in the treatment of HCC
is the transcatheter angiographic delivery of Yttrium-90 (90Y)
microspheres that is indicated for metastatic colorectal carcinoma
(CRC) as well as HCC (5). Typically, under fluoroscopic guidance,
the arterial catheter is optimally placed and the radiolabeled parti-
cles injected into the vascular distribution of the tumor. Injection
through the hepatic artery provides 90Y treatment with an advan-
tage over other modalities, since hepatic malignancies receive
approximately 70–80% of their blood supply via the hepatic artery
(6). The injected particles then become trapped at the precapillary
level, and emit internal [β] radiation, providing more localized,
higher dose delivery as compared to external beam radiation (5).
At the same time, surrounding normal liver tissue that is perfused
primarily from portal vein circulation is relatively preserved.
The Radioembolization and Brachytherapy Oncology Con-
sortium (REBOC) recommends that because the nature of pri-
mary and secondary hepatic malignancies differs, therapy should
be tailored to the disease (7). For example, according to one
study, multinodular HCC without vascular invasion needs to be
treated by transarterial chemoembolization, while HCC with vas-
cular invasion or distant metastasis is suited for treatment with
sorafenib, a targeted multikinase inhibitor administered orally
(8). Additionally, according to REBOC, patients with liver metas-
tases from other primary sites should be offered systemic therapy
before 90Y treatment, and in the case of primary hepatic tumors,
patients should undergo hepatology and transplant evaluations to
determine the optimal treatment strategy (7). A study by Gulec
et al. demonstrated that 90Y microsphere selective internal radia-
tion treatment effectively controls tumor growth, with a possible
induction of contralateral lobe hypertrophy (4).
YTTRIUM-90
Intravascular delivery of the radioactive isotope yttrium-90 has
been practiced since the mid 1960s (9). The use of microspheres
embedded with a β-emitting radionuclide, such as Yttrium-90, has
been available to investigators in the United States since 2000 (6, 7).
90Y is produced by neutron bombardment of Y-89 in a com-
mercial reactor. 90Y is a beta radiation emitter having average
energy of 0.94 MeV, with a mean tissue penetration of 2.5 mm,
and a maximum range of 1.1 cm. One gigabecquerel of 90Y deliv-
ers approximately 49.38 Gy/kg to tissue. The half-life of 90Y is
2.67 days or 64.2 h (7).
90Y POSITRON EMISSION TOMOGRAPHY/COMPUTERIZED
TOMOGRAPHY
While many studies have supported the benefits and advantages
of HCC treatment with 90Y, there are multiple factors that must
be considered. In a review of the relevant literature, Pasciak et al.
have noted that 90Y positron emission tomography/computerized
tomography (PET/CT) is capable of providing accurate infor-
mation with regard to the microsphere distribution in a lesion.
They also noted that activity concentration for 90Y can be quanti-
fied with or without time-of-flight acquisition. However, despite
known methods to calculate dose, there is no standardized method
of dosimetric measurement (10).
In early clinical trials, it was assumed that the activity and
distribution of the 90Y particles were uniform throughout the
liver. However, recent analyses of livers that had been imaged
or explanted have demonstrated that uniform distribution is not
the case (11). Due to the radiolucency of the 90Y microspheres,
real-time monitoring of treatment and distribution is not possi-
ble during the infusion process (12). To address this, methods to
monitor distribution of 90Y have been developed.
Kao et al. note that the distribution of microsphere therapy
within the target arterial territory is dependent upon locoregional
flow environment distal to the point of injection, the injection rate,
the timing interval,proximity to branching daughter vessels, extent
of lung shunting, cardiovascular status, and particle load (13).
Their study compared the previously held gold-standard for post-
90Y microsphere radioembolization imaging, 90Y Bremsstrahlung
SPECT/CT, with 90Y PET/CT. The study’s conclusion was that
90Y PET/CT is superior to 90Y Bremsstrahlung SPECT/CT for the
assessment of target and non-target activity (13).
Zade et al. demonstrated the superiority of 90Y PET/CT over
90Y Bremsstrahlung SPECT/CT. While β radiation emitted by 90Y
interacts with body tissues resulting in Bremsstrahlung radiation,
which has conventionally been used for imaging the biodistrib-
ution of this isotope, the wide energy range of Bremsstrahlung
radiation makes imaging involving 90Y technically challenging
(12). Elschot et al. have also demonstrated that 90Y PET/CT is
superior to Bremsstrahlung SPECT/CT because of its superior
resolution and lack of specialized techniques for quantification of
images while utilizing comparable image acquisition time (14).
Owing to the success of 90Y PET/CT, other researchers have
used this valuable tool as a means of developing a dose calcula-
tion technique based on the observed distribution of microspheres
after infusion (15, 16). Others have reported a 40-Gy increase in
absorbed dose to tumor and complete resolution of disease in
the treated area within 3 months by optimizing treatment from
observed 90Y PET/CT activity (17, 18).
The purpose of this study is to utilize 90Y PET/CT to determine
the dosimetry to tumors and normal liver post-radioembolization
treatment and the relationship of dose to outcome.
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MATERIALS AND METHODS
PHANTOM EXPERIMENT
The IEC body phantom experiment was performed in order to
assess the PET camera’s ability to image 90Y quantitatively. Scans
were performed on day 0, day 3, day 5, and day 7 after loading
the phantom with a liquid 90Y chloride solution using a PET/CT
camera (Siemens Biograph mCT) having 22 cm PET axial field of
view and capable of time-of-flight PET. CT images were obtained
immediately prior to the PET scan for the purpose of attenuation
correction and scatter correction. Prior to imaging, the phantom
was prepared using 90Y chloride solution with activity (3.15 GBq)
calibrated by the supplier (Perkin-Elmer, Waltham, MA, USA). An
abdominal-shaped container was filled to capacity with 9.717 mL
of sterile water in the background compartment mixed with 10 g
DTPA. Six spheres (of diameters 37, 28, 22, 17, 13, and 10 mm)
located on the container’s center plate were filled with 90Y solution
to approximately an 8:1 ratio, and a 3D acquisition and reconstruc-
tion protocol of the phantom was created. The protocol included
two bed positions with duration of 20 min per position. Since 90Y
PET is a rather novel scan procedure, the scanner software did
not allow the selection of 90Y, thus Ge-68 was selected instead,
with correction for the relative positron branching fractions made
later (see below). The PET reconstruction protocol utilized the
3D OSEM algorithm including time-of-flight information and
point spread function modeling with 2 iterations, 21 subsets, 8 mm
Gaussian filter, and zoom factor 1.0. The reconstruction included
corrections for attenuation, scatter, random coincidences, detector
normalization, and dead time.
The result of the phantom experiment revealed that our Bio-
graph mCT PET scanner was able to estimate the known 90Y
activity filled in the spheres to an average accuracy of−4.8% [range
−15–2.2%] for the spheres of 37 and 28 mm diameter.
OVERVIEW OF PATIENTS TREATED AND CALCULATION OF NORMAL
LIVER ACTIVITY
In this Institutional Review Board approved and Health Insur-
ance Portability and Accountability Act compliant retrospective
study, 56 HCC patients treated with TheraSpheres® (BTG, London,
UK) were studied between December 7, 2010 and May 22, 2013.
The main purpose was to evaluate the radiation absorbed dose
by tumors and the radiation absorbed dose by the region of nor-
mal non-malignant liver tissue that is incidentally treated by 90Y
microsphere therapy. Both glass and resin microspheres are used
at our center but only glass microspheres (TheraSpheres®) were
included in this study. The 90Y activity was prescribed according
to the manufacturer recommended guidelines, using the stan-
dard MIRD-based formula [Dose= 49.38 (Activity/mass)].(7)
Our institutional practice is to give the 90Y activity that will
result in each lobe of the liver receiving ~120 Gy. Using a spe-
cialized imaging program from MIM software (Cleveland, OH,
USA), contours were drawn on CT images to highlight and iso-
late tumor volumes, as well as the volumes of liver treated by 90Y
microspheres. The software was used to identify the volume of the
contoured region, as well as the activity concentration of the con-
toured region in Bq/mL using the contour statistics tool. The MIM
software allowed us to determine volumes and activity concentra-
tion for the entire treated liver region and the tumor regions, but
the subdivision described below, modified slightly from what has
been presented in the literature (19), needed to be employed to
evaluate the activity concentration of the normal non-malignant
liver tissue that was also contained in the treated region.
The following subdivision is assumed, where Ax represents the
total activity of the region x in Bq:
ATreated liver = ATumor + ANormal liver (1)
Since Ax= (Cx)(V x), where Cx is the activity concentration of
region x in Bq/mL and Vx is the volume of the region x in mL,
Eq. 1 can be rewritten as:
(VTreated liver) (CTreated liver) = (VTumor) (CTumor)
+ (VNormal liver) (CNormal liver) (2)
Algebraic rearrangement of Eq. 2 with the use of the iden-
tity (VNormal liver)= (V Treated liver)− (V Tumor) provides us with
the activity concentration of normal liver:
(CNormal liver) = (VTreated liver) (CTreated liver)− (VTumor) (CTumor)
(VTreated liver)− (VTumor)
(3)
If multiple tumors were present, then (V Tumor)(CTumor) in
Eq. 3 was replaced by the following equation:
(VTumor) (CTumor)= (VTumor 1) (CTumor 1)+ (VTumor 2) (CTumor 2)
+ (VTumor 3) (CTumor 3) ... (4)
Following activity concentration determination, activity con-
centration (Bq/mL) for tumor and normal liver were converted to
an absorbed dose (Gy) by using an absorbed dose factor that will
be discussed later in the Section “90Y absorbed dose calculation”.
TREATED LIVER VOLUME AND ACTIVITY DETERMINATION
The attenuation correction CT (AC CT) that is acquired with the
PET scan following 90Y radioembolization was used to contour
the volume of treated liver (i.e., right lobe or left lobe). The 90Y
PET scan and the accompanying AC CT were analyzed using MIM
software. A fusion of the PET and AC CT was viewed in order to
visualize which regions of the liver were targeted and contained
the most activity. The treated lobe volume was contoured on the
AC CT using a contour tool in MIM. Contours were individually
drawn in the axial view of the AC CT. Contours were drawn on
each plane to ensure that the entire treated region was encom-
passed. The region of treatment was determined by examining
the 90Y PET activity distribution on the fusion image and also
by viewing medical records of the 90Y microsphere therapy pro-
cedure that indicated the intended target liver lobes for therapy.
After the contours were drawn, the contour statistics tool in MIM
was used to display the volume of the contour region in mL and
the activity concentration of the contour region in Bq/mL (see
Figure 1). Three trainees contoured both liver and tumor vol-
umes under the supervision of a board certified nuclear medicine
physician.
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FIGURE 1 |This image shows a contour in pink drawn around a treated
region in an axial slice of the AC CT/PET fusion image that was
acquired following right lobe 90Y microsphere therapy.
TUMOR CHARACTERIZATION AND DEFORMATION
The triphasic abdominal CT scans that were acquired most
recently prior to 90Y microsphere therapy were used to contour
tumor volumes. The tumor volume was visualized in either the
arterial or venous phase CT, and the tumor was contoured. Con-
tours were individually drawn in the axial view of the either arterial
phase obtained 30 s post-injection or the venous phase obtained
60 s post-injection. Multiple contours were used if multiple tumors
were present. Tumors that were present in the liver but not in the
intended region of therapy were not contoured. The tumor regions
were determined by examination of the arterial and venous phase
CT scans and were confirmed by reading the CT imaging reports
with respect to specific information about hepatic morphology
and tumor location.
The 90Y PET/CT scan, which was required for determination of
tumor radioactivity, typically showed poor overlap with the arte-
rial and venous phase CT scans due to variations in position of
patient, free breathing vs. breath hold, and time gap between the
two acquisitions (see Figure 2). For this reason, the abdominal CT
scan on which the tumor contours were drawn was deformed to
match the AC CT corresponding to the PET scan using the defor-
mation tools in MIM. The “reg refine” tool in MIM allowed us to
fix points of interest that should be conserved in the deformation
process. These points were mostly fixed around the liver edges since
this was our organ of interest. Around 60 points were fixed around
the liver in multiple planes and then the local alignments were
converted into a deformable registration using the MIM deforma-
tion tool. The tumor contours drawn on the abdominal CT were
deformed in the process as well.
This process provided a deformed abdominal CT scan that
showed increased similarity of liver morphology to the AC CT/PET
fusion scan, which ensured more accurate determination of tumor
volumes and radioactivities compared to the undeformed scan
FIGURE 2 | (A) shows a pink contour drawn around a tumor in an axial slice
of the arterial phase abdominal CT scan. (B) shows the same tumor contour
overlaid on the AC CT/PET fusion image that was acquired following left
lobe 90Y microsphere therapy. (B) exhibits that contours drawn on the
arterial CT show poor overlap with the corresponding region in the AC
CT/PET fusion image. This can lead to inaccurate activity concentration
determinations and necessitated the need to deform the arterial CT scan
for more accurate contour statistic calculations.
(see Figure 3). The compute “contour statistics” tool evaluated the
contoured tumor region and displayed the volume of the contour
region in mL and the mean activity concentration in Bq/mL. Mul-
tiple sets of values were obtained if multiple tumors were present.
The mean activity concentration (Bq/mL) of the tumor can be
converted to an absorbed dose (Gy) of the tumor by using the
absorbed dose factors that were determined from branching ratios
as explained in the next section.
90Y ABSORBED DOSE CALCULATION
Our calculation utilized dosimetry based on a modification to
the local deposition model using 90Y post-radioembolization dose
(11, 20, 21) as opposed to technetium-99m macroaggregated albu-
min SPECT images (18, 22). Following determination of the mean
activity concentration of the tumors and normal liver, the activ-
ity concentration in Bq/mL needed to be converted to absorbed
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FIGURE 3 | (A) shows a pink contour drawn around the tumor in an axial
slice of the deformed version of the arterial phase CT scan that was shown
in Figure 2A. (B) shows the same tumor contour overlaid on the same AC
CT/PET fusion scan shown in Figure 2B that was acquired following left
lobe 90Y microsphere therapy. (B) exhibits that contours drawn on the
deformed arterial CT show good overlap with the corresponding region of
interest in the AC CT/PET fusion image. Because this allows for more
accurate contour statistic calculations, the deformation tools in MIM were
utilized.
doses of 90Y in units of Gy. On the PET acquisition workstation,
the radionuclide Ge-68 was selected since 90Y was not available
for selection. Ge-68 is long lived (half-life of 270.8 days) and
decays to Ga-68, which is short lived (half-life of 68 min) and has
high positron branching (0.891). The radioactivity concentration
measured by the PET scanner (CGe) is in terms of Ge-68/Ga-68
positron events and has units of Bq/mL. The first step was the con-
version of the radioactivity concentration in terms of Ge-68/Ga-68
positron events into a radioactivity concentration in terms of 90Y
positron events (CY), which is also in units of Bq/mL. This was
done using the ratio of branching coefficients for Ge-68/Ga-68
and 90Y (23).
(CGe)
(
0.891 β+/Ge-68 decay
)(
0.0000316 β+/90Y decay
) = CY (5)
The CY was then divided by a factor of 106 and multiplied by
the absorbed dose factor 49.38 in order to convert Bq/mL into
units of Gy (6). Decay was taken into account between the time of
injection of 90Y and the time of PET scan. The overall conversion
of the radioactivity concentration in terms of Ge-68/Ga-68 decay
(CGe) that is determined by the scanner, into a dose of absorbed
90Y (D90Y) can be represented by the following equation:
(CGe)
(
0.891 β+/Ge decay
)
(49.38) et(ln2)/64.1(
0.0000316 β+/Y decay
) (
106
) = D90Y (6)
This formula, nearly identical to the conversion factor used by
Pasciak et al. (21), was used for all radiation dose calculations for
both tumors and normal liver.
STATISTICAL METHODS
Tumor response was divided into two categories for analysis: treat-
ment responders vs. non-responders. Responders were defined
as complete response, partial response, or enough remittance
of tumor burden to enable a liver transplant. Treatment non-
responders were defined as stable disease, progressive disease, or if
the patient died before the treatment response could be assessed. A
logistic regression model was built at the tumor level. The depen-
dent variable was the modified response evaluation criteria in
solid tumors (mRECIST) outcome dichotomized as responders vs.
non-responders. The independent variable was the tumor (Gy) in
the liver segment. Generalized estimating equations (GEEs) were
used to account for the correlation in multiple lesions from the
same patient. A significance level of 0.05 was used to test for an
association between dose and the probability of response.
An additional analysis was performed to explore a possible
correlation between dose of radiation to normal liver tissue and
complications suffered within 2 months of 90Y radioembolization.
Complications included abnormal liver function tests, right upper
quadrant pain, ascites, cholecystitis, or physician notes indicat-
ing poor response and functional status of the patient following
therapy. Those patients who had only slight fatigue and slight
abdominal pain were grouped with patients who had no com-
plications. The remaining complications were considered severe.
Logistic regression models were built to predict severe compli-
cations as a function of Gy delivered to normal liver tissue. The
dependent variable was the presence/absence of severe complica-
tions; the independent variable was the Gy to the normal liver. A
significance level of 0.05 was applied to test the effect of dose.
RESULTS
The analysis on our cohort suggests that the mean dose received
among the 98 studied tumors was 169 Gy with a mode of 90–
120 Gy and a treatment dose range of 0–570 Gy. The overall
distribution of doses delivered to tumor is displayed in Figure 4.
Additionally, Figure 5 indicates the relationship between tumor
dose and tumor volume. This scatter plot shows the inherent dif-
ficulty in achieving a substantial Gy in a tumor of large volume.
If one were to consider >100 Gy to be a treatment goal (6), then
clearly the majority of the tumors in which this was achieved were
smaller than 100 mL in volume.
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Tumor 
  Dose
Range 
  (Gy)
0-30 30-60 60-90 90-120 120-150 150-180 180-210 210-240 240-270 270-300 300-330 330-360 360-390 390-420 420-450 450-480 480-510 510-540 540-570 570-600
Tumor Dose Frequencies 4 8 12 18 8 9 10 6 9 2 3 3 2 1 0 2 0 0 1 0
0
2
4
6
8
10
12
14
16
18
20
Tumor Dose Frequencies (98 Total Tumors)
Average Tumor Dose: 169.40 Gy 
  Standard Deviaon: 109.10 
  Median: 146.5 Gy
Mode:90-120 Gy 
   
  
FIGURE 4 |The above chart displays the frequencies of radiation doses delivered to tumor tissue in the 56 cases of 90Y radioembolization therapy for
hepatocellular cancer that were analyzed.
FIGURE 5 |This figure shows a scatter plot representation of tumor dose (Gy) in relation to tumor volume (mL).
Modified response evaluation criteria in solid tumors were used
to assess the overall tumor response to radioembolization therapy.
mRECIST guidelines state that lesions are suitable for mRECIST
criteria if they can be classified as a RECIST measurable lesion, the
lesion is suitable for repeat measurement, or the lesion shows intra-
tumoral enhancement on contrast-enhanced CT or MRI. Target
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lesion responses to therapy were classified as complete (CR), par-
tial (PR), stable (SD), or progressive disease (PD) based on their
respective change in size and contiguous intratumoral enhance-
ment on arterial phase CT or MRI. Size change measurements were
based on the longest enhancing tumor diameter per mRECIST
guidelines. The mRECIST analysis was performed by a medical
student with oversight from an abdominal radiologist. Lesions
qualified as a CR if there was a disappearance of intratumoral
arterial enhancement (vis-a-vis total necrosis). PR involved a 30%
decrease in the diameters of viable target lesions, whereas pro-
gressive disease demonstrated an increase of at least 20% in the
diameters of viable lesions. SD did not meet the criteria for either
a PR or PD (24).
Fifty-seven of the 98 tumors that were assessed for dosage were
deemed acceptable to be assessed for tumor response. They met the
following characteristics: hyper-enhancing on arterial phase of CT
or MRI, hypo-enhancing on venous phase of CT or MRI, and size
greater than or equal to 2 cm. If <2 cm, they had to show organ
procurement and transplantation network (OPTN) 5A criteria
to ensure accurate analysis as well as reduce quantitative errors,
which could arise from smaller lesion sizes as shown by Willowson
et al. (25).
The transplant recipient’s tumors (n= 2, mean 142 Gy) and the
deceased patients’ tumors (n= 7, mean 221 Gy) were unable to be
assessed by mRECIST due to not having post-treatment images.
Thus, data analysis was performed on the 48 tumors in 33 patients
who were able to be stratified with an mRECIST score, revealing
21 responders and 27 non-responders with a mean tumor (Gy)
of 215 and 167, respectively (see Tables 1 and 2). The association
between mean tumor (Gy) and response was not statistically sig-
nificant (p= 0.099) (Table 3) but was suggestive of a trend for
greater likelihood of a response as tumor (Gy) increased.
Tumor response was divided into two categories for analy-
sis: treatment responders vs. non-responders. Responders were
defined as complete response, partial response, or enough remit-
tance of tumor burden to enable a liver transplant. Twenty-three
tumors were found to be responders per this definition (see
Table 1). Treatment non-repsonders were defined as stable dis-
ease, progressive disease, or if the patient died before the treatment
response could be assessed. Thirty-four tumors were found to be
treatment non-responders per this definition (see Table 2). Data
analysis done on the 48 tumors in 33 patients who were able to
be stratified with an mRECIST score revealed 21 responders and
27 non-responders with a mean tumor absorbed dose of 215 and
Table 1 |The below table illustrates the responses of 23 separate tumors deemed to be “responders” after 90Y radioembolization treatment
resulted in complete or partial response or enough remittance of tumor burden to enable a liver transplant.
90YTumor responders (tumor response categorized by mRECIST)
Liver segment(s) Mean tumor (Gy) Tumor size before
treatment (cm)
Tumor size at
follow-up (cm)
Elapsed time to
follow-up (months)
Overall response
Left lobe 114 1.7 2.6 (all necrotic) 2.6 Complete
5,8 372 5.8 3.2 5.9 Partial
2 104 2.5 1.7 3.7 Partial
3 190 4.6 2.6 3.7 Partial
6,7 79 2.2 1.5 3.0 Partial
2 469 1.9 1.1 (all necrotic) 4.5 Complete
3 87 1.9 all necrotic 4.5 Complete
8 147 4.1 4.2 (all necrotic) 4.5 Complete
6 555 3.8 1.0 3.3 Partial
2 349 4.4 2.9 (all necrotic) 5.9 Complete
8 207 1.8 3.2 (all necrotic) 5.5 Complete
8 17 2.2 1.0 3 Partial
7 269 3.6 1.9 3 Partial
6 131 6.4 4.0 5.9 Partial
6 405 4.3 1.0 1.9 Partial
1 259 2.8 1.6 4.1 Partial
4 153 2.3 2.7 (all necrotic) 7.3 Complete
5 30 11.8 3.7 7.3 Partial
4B 115 4.6 0.9 2.7 Partial
2,3 158 6.5 4.1 2.6 Partial
2 301 2 0.9 (all necrotic) 2.5 Complete
8 22 1.2 – – Liver transplant
5 261 1.7 – – Liver transplant
The overall responses were based on mRECIST criteria. Of these 23 tumors that were deemed to be responders, 8 had complete response, 13 had partial response,
and 2 had remittance of disease that allowed liver transplant.
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Table 2 |The below table illustrates the responses of 34 separate tumors deemed to be “non-responders” after 90Y radioembolization.
90YTumor non-responders (tumor response categorized by mRECIST)
Liver segment(s) Mean tumor (Gy) Tumor size before
treatment (cm)
Tumor size at
follow-up (cm)
Elapsed time to
follow-up (months)
Overall response
Lateral right lobe 209 3.2 3.1 7.5 Stable
4A,8 465 5.3 10.2 7.3 Progressive disease
8 78 5.1 5.3 3 Stable
2 212 2.2 1.6 1.6 Stable
Right lobe 46 1.5 1.5 4.3 Stable
5 362 4.2 3.4 8.1 Stable
6 279 13.1 13.4 8 Stable
8 200 3.9 3.7 4.4 Stable
Right lobe 233 9.4 8.3 7.6 Stable
2,3 207 3.2 4.2 2.3 Progressive disease
2 124 3.7 3.1 2.3 Stable
4B 270 1.8 2 2.3 Stable
8 275 2.2 2.4 2.3 Stable
8 35 2 2.2 3 Stable
6 233 3.2 2.8 3 Stable
Right lobe 63 9.7 8.6 5.8 Stable
6 103 3 2.7 5.3 Stable
6 78 3.6 3.4 6.9 Stable
7 234 3.1 3.1 2.6 Stable
7 46 2.6 2.5 2.7 Stable
8 76 2.8 2.8 2.6 Stable
Left lobe 92 9.9 7.5 3.1 Stable
5 117 4.2 3.7 4.4 Stable
7 62 5.3 4.8 4.8 Stable
8 217 2.1 2.5 4.8 Stable
6 160 2.6 3.2 1.4 Progressive disease
6 40 4.1 3.9 7.5 Stable
Right lobe 153 8.6 – – Patient deceased
6, 7 327 5.6 – – Patient deceased
8 146 5 – – Patient deceased
Left lobe 169 1.3 – – Patient deceased
8 353 1.9 – – Patient deceased
7 265 2.2 – – Patient deceased
6 132 3 – – Patient deceased
For this study, non-responders were defined by stable disease, progressive disease, or if the patient died before the treatment response could be assessed. The
overall responses were based on mRECIST criteria. Of these 34 tumors that were deemed to be non-responders, 24 had stable disease, 3 had progressive disease,
and 7 tumors were unable to be assessed for response due to death.
167 Gy, respectively. A logistic regression model was built at the
liver segment level. The dependent variable was the mRECIST
outcome dichotomized as CR and PR as responders, and SD and
PD as non-responders. The independent variable was the tumor
(Gy) in the liver segment. GEEs were used to account for the corre-
lation in multiple segments from the same patient. A significance
level of 0.05 was used to evaluate the effect of tumor dosage on
outcome. The association between mean tumor absorbed dose
and response did not reach statistical significance due to a p-value
of 0.099 (see Table 3). The transplant recipient’s tumors (n= 2,
mean 142 Gy) and the deceased patients’ tumors (n= 7, mean
221 Gy) were unable to be assessed by mRECIST due to not having
post-treatment images.
Normal liver tissue in the 56 cases evaluated received a mean
absorbed dose of 67 Gy with a mode of 60–70 Gy and a range of
10–120 Gy. The overall distribution of doses delivered to normal
treated liver lobe is displayed in Figure 6.
An additional analysis of the 56 cases in this study was
done to explore a possible correlation between dose of radia-
tion to normal liver tissue and complications suffered within
2 months of 90Y radioembolization (see Figure 7). The graph
displays that in 23 of the 56 cases, no complications were
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observed in the 2 months following procedure. In the remain-
ing 33 cases in which complications were suffered, the most
common complication was slight fatigue, experienced in 14 of
the cases. Ascites and moderate to severe fatigue were the next
most common complications, which were experienced in seven
cases and six cases, respectively. Jaundice and severe chest pain
were the least common complications, which were each seen
in one case. Thirty-seven had mild or no complications (i.e.,
slight fatigue, slight abdominal pain, and no symptoms), 15
had one severe complication, and 6 had two or more severe
complications.
Table 3 | Statistical analysis of the 48 tumors evaluable by mRECIST
criteria, which had follow-up scans available.
Outcome (n) Mean tumor
dose (Gy)
Standard
deviation (Gy)
Dose
range (Gy)
CR (n=8) 228 133 87–469
PR (n=13) 206 160 17–555
SD (n=24) 154 96 35–362
PD (n=3) 277 164 160–465
Responders (CR and PR) 215
Non-responders (SD and PD) 167 p=0.099
Patients who went to transplant or died were excluded. There were 21 respon-
ders and 27 non-responders. The association between mean tumor (Gy) and the
response may indicate a trend, but was not statistically significant (p=0.099).
The absorbed dose in the normal liver varied from a low of
15 to a high of 115 Gy, with mean and median of 67. Among the
37 patients with no to mild complications, the mean absorbed
dose was 65.2 Gy; among the 15 patients with one severe com-
plication the mean absorbed dose was 64.0 Gy, and among the
6 patients with two or more severe complications, the mean
absorbed dose was 87.2 Gy. There was a statistically significant
association between liver absorbed dose and the presence/absence
of two or more severe complications (p= 0.036). For patients with
absorbed doses<75 Gy, the probability of two or more severe com-
plications was 5% (2/40), the odds being 2/38; for patients with
absorbed doses of 75–95 Gy, the probability was 20% (2/10), the
odds being 2/8; and for patients with absorbed doses of >95 Gy,
the probability was 25% (2/8), the odds being 2/6. For patients
with doses of 55–75 Gy, we observed that the probability of two or
more severe complications was 0.087 (2 of 23 patients), the odds
were 2/21. Therefore, over the increase in Gy from 55–75 to 75–95,
the risk of two or more severe complications increases 2.6 times
(2/21: 2/8). From the fitted model, the odds ratio for a single unit
increase in absorbed dose was 1.049, with 95% CI of [1.003, 1.096]
for patients in this study with a dose range of 20–115 Gy. Statistical
modeling for our cohort suggests that for every 10 Gy increase in
the liver, there is an estimated 61% increase in the odds that the
patient will have two or more severe complications.
DISCUSSION
Radioembolization is really a form of brachytherapy. Radiation
oncologists, who regularly perform prostate brachytherapy with
Normal
Lobe
Dose
Range
(Gy)
0-10 10-20 20-30 30-40 40-50 50-60 60-70  
  
70-80 
  
80-90 90-100 100-110 110-120 120-130
Normal Treated Lobe Dose Frequencies 0 1 3 2 6 8 11 10 6 3 3 3 0
0
2
4
6
8
10
12
Normal Treated Lobe Dose Frequencies (56 Total Cases)
Average Normal Treated Lobe Dose:66.95 Gy
Standard Devia!on:23.17
Median Dose: 66.55 Gy
Mode: 60-70 Gy
FIGURE 6 |The above chart displays the frequencies of radiation doses delivered to normal liver tissue in the 56 cases of 90Y radioembolization
therapy for hepatocellular cancer that were analyzed.
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FIGURE 7 |The figure above indicates the symptoms experienced after 90Y radioembolization for the 56 cases evaluated in this study. Patients in
certain cases had multiple complications. Complications reported were those that had occurred within 2 months of procedure.
seed implants or cervical/endometrial brachytherapy with tan-
dem and ovoids, have an understanding of the dose in Gray (Gy)
delivered to tumors as well as the dose delivered to normal pelvic
structures. This basic understanding is essential if one is to maxi-
mize delivery to tumor and minimize collateral damage to normal
tissue. Up until now, radioembolization has been largely practiced
without a strong sense for the quantity of radiation exposure to
liver tumors vs. normal liver.
Lhommel, in 2009, opened a new era by demonstrating that
it is possible to image the pair production positron from 90Y
using PET/CT (26). While the biodistribution map that comes
from 90Y PET/CT scan is itself very useful for determining the
extent of treatment coverage, it is the quantitative aspect of PET
that is still largely untapped. Now with the ability to quantify
the amount of 90Y deposited in tumor and normal liver tissue
regions, we can begin to understand what effect we are having on
the patient. One goal is to eventually mirror that which is done in
conventional brachytherapy by treating tumors to a certain level
of Gy or by mandating that normal liver does not exceed a certain
threshold. But even more basic than this is to understand what
absorbed dose is truly considered tumoricidal and what absorbed
dose can be safely administered to normal liver tissue with accept-
able side effect profile. With the advent of quantitative 90Y PET/CT
and image-based dosimetry, we can begin to address these larger
questions.
Although the results of treatment responder and non-
responder analysis did not prove to be statistically significant
(p= 0.099), the data suggest a possible trend that a higher 90Y dose
resulted in better response in those tumors able to be definitively
analyzed. A larger sample size is needed to possibly reinforce this
suggestion. With the above possibility in mind, the data from
the analysis suggest a minimum tumor absorbed dose of around
150 Gy to get enough of a response to at least stabilize the targeted
tumor. This was indicated by how stable disease response had a
mean tumor absorbed dose of 154 Gy. The tumors that showed
progressive disease with a mean tumor absorbed dose of 277 Gy
may have been a statistical anomaly with n= 3, in that the high
dosage may just be random occurrence. If the sample size were
larger and statistical significance achieved, one could come to the
conclusion that an absorbed dose>200 Gy will result in the patient
being a responder. Alternatively, if no trend can be demonstrated,
one may conclude that an absorbed dose >150 Gy may be suffi-
cient for at least a tumorostatic treatment resulting in SD. Likely,
all four outcomes had mean (Gy) doses in a therapeutic range, with
simply aggressive tumors in the PD group. An analysis with greater
numbers would help in elucidating the tumoricidal vs. tumoro-
static threshold. Interestingly, our distribution of responses using
mRECIST criteria is strikingly similar to that seen in the work of
Strigari et al. (27).
The complications from hepatotoxicity show that dose deliv-
ered to normal liver is an important parameter to consider when
treating radioembolization patients. When looking at Figure 7,
one can appreciate the large range of liver dosage that patients
receive. In addition, the complications vary widely, from no symp-
toms to severe adverse events. The idea that a threshold activity
to the normal liver should not be crossed may help reduce the
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incidence of such events. As referenced in Strigari et al., her tol-
erance dose of the liver leading to 50% complication probability
(TD50) was 52 Gy (27). In our cohort, 93% of patients received a
dose of 30 Gy or larger to normal liver, with 13% of these patients
experiencing some sort of complication and 11% experiencing two
or more severe complications. Only one patient of four receiving
a dose <30 Gy experienced any complications, though it was a
severe one. It is likely that a threshold of 30 Gy to normal liver
would have greatly reduced the incidence of complications.
Multiple studies have exposed the limitation of using size-based
response criteria, such as RECIST, with the use of biologic targeted
therapy and transcatheter therapy. In the SHARP trial, which stud-
ied the use of sorafenib in treatment of advanced HCC, up to 70%
of patients who responded favorably and had a longer progres-
sion free survival had stable disease by size, but demonstrated
morphologic changes such as necrosis (28). In 2000, a panel of
experts on HCC convened by the European Association for the
Study of the Liver (EASL) amended the response criteria to take
into account tumor necrosis induced by treatment (24). Later,
Lencioni and Llovet based on consensus panel of American Asso-
ciation for the Study of Liver Diseases and Journal of the National
Cancer Institute members tweaked existing size-based criteria and
found modified RECIST superior in assessing treatment response
of loco-regionally treated HCC. mRECIST is based on long axis
diameter measurement of the enhancing portions of the target
lesions that are selected using comparable guidelines as RECIST.
Likewise, response assessment categories or PD, PR, SD, and CR
with percent change in the measured long axis of target lesion is
also similar to that of RECIST (29). Modified RECIST has been
shown to out-perform RECIST in accuracy and in its ability to
predict outcomes in transcatheter treated HCC patients.
An obvious limitation to the methods presented in this paper
is the fact that the activity given to normal liver is not explic-
itly calculated from a volume of interest. Since the normal liver
volume or contour is sometimes difficult or laborious to define,
we used the subdivision explained in the Section “Materials and
Methods.” The effect of this methodology is that the activity to
this region is averaged over the entire volume. Thus, any statistical
“hot spots” or “cold spots” will not be appreciated. Of course, this
is an approximation, since it is highly probable that distribution
of 90Y microspheres to the normal liver will be heterogeneous and
not homogeneous. If adverse events occur in patients who have
intense focal delivery to normal liver, as opposed to some thresh-
old value of Gy, we will not be capturing those occurrences, as our
model distributes that focal activity evenly throughout the normal
liver volume.
Another limitation is that HCC was the only diagnosis studied.
It is possible that other types of tumors such as cholangiocar-
cinoma, or metastases from colorectal cancer, neuroendocrine
tumors, breast cancer, uveal melanoma, prostate cancer, etc., could
respond differently. Analogous types of analyses need to be per-
formed with other tumors and metastases to see if our findings are
disease specific or are generalizable across different pathologies.
CONCLUSION
This study provides a simple and systematic methodology for
calculation of radiation absorbed dose for both tumors and
normal liver in 90Y radioembolization. The authors believe
that quantitative 90Y PET/CT image-based dosimetry provides
a greater understanding of tumor response and the subsequent
clinical outcomes. Our cohort of patients showed a possible dose–
response trend for the tumors, and complications resulting from
dose to normal liver. These methods in the future can provide the
tools to help understand whether patient adverse events, treatment
success, or treatment failure can be attributed to the dose that the
tumor or normal liver received.
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